Clinical Trial Update: Ipilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of ipilimumab plus nivolumab in molecularly selected castration-resistant prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• OPDIVO (nivolumab)
• Yervoy (ipilimumab)

Snippet

Sponsor: Radboud University Medical Center | Conditions: Prostatic Neoplasms, Castration-Resistant | Phase 2 | Status: COMPLETED